Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2020 16:05 ET | Source: KemPharm

KemPharm Reports First Quarter 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m. ET Corporate and Regulatory Highlights: KP415 NDA filing accepted by FDA on May 1, 2020KemPharm...
May 06, 2020 16:15 ET | Source: KemPharm

KemPharm to Report First Quarter 2020 Financial Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Tuesday, May 12, 2020, 5:00 p.m. ET CELEBRATION, Fla., May 06, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a...
May 04, 2020 08:00 ET | Source: KemPharm

NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

Corium, GPC’s portfolio company, to lead all commercialization activities for KP415 CELEBRATION, Fla., May 04, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical...
March 02, 2020 16:18 ET | Source: KemPharm

KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products ...
February 28, 2020 07:30 ET | Source: KemPharm

KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

KP415 NDA Remains on Track for Q1 2020 Submission CELEBRATION, Fla., Feb. 28, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery...
January 15, 2020 08:30 ET | Source: KemPharm

Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today CELEBRATION, Fla., Jan. 15, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical...
December 18, 2019 07:15 ET | Source: KemPharm

KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date KemPharm Will Host a Conference Call...
November 14, 2019 16:55 ET | Source: KemPharm

KemPharm Reports Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 14, 2019, at 5:30 p.m. ET CELEBRATION, Fla., Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:...
November 12, 2019 08:30 ET | Source: KemPharm

KemPharm to Report Third Quarter 2019 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled forThursday, November 14, 2019, 5:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc....
October 31, 2019 08:30 ET | Source: KemPharm

KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access CELEBRATION, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company...